| 產(chǎn)品名稱 | Primary Umbilical Vein Endothelial Cells; Normal, Human, Pooled (HUVEC) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 商品貨號(hào) | B236167 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Organism | Homo sapiens, human | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tissue | Umbilical | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cell Type | Endothelial | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Morphology | Cobblestone appearance with large dark nuclei; during proliferation, cells are small and evenly sized, display a high mitotic index and show no presence of smooth muscle cells. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Growth Properties | Adherent | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Biosafety Level | 1 [These primary cells are not known to harbor an agent recognized to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. Cells derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens. ATCC recommends that appropriate safety procedures be used when handling all primary cells and cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures are provided in Laboratory Safety: Principles and Practice, 2nd ed. (ASM Press, Washington, DC) (Fleming et al., 1995) and Caputo, J.L. Biosafety procedures in cell culture. (1988) J. Tissue Culture Methods 11:223. Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online at http://www.cdc.gov/biosafety/publications/bmbl5/index.htm.] Human Material Precaution All tissues used for isolation are obtained under informed consent and conform to HIPAA standards to protect the privacy of the donor’s personal health information. It is best to use caution when handling any human cells. We recommend that all human cells be accorded the same level of biosafety consideration as cells known to carry HIV. With infectious virus assays or viral antigen assays, even a negative test result may leave open the possible existence of a latent viral genome. Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disease | Normal | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age | Neonatal | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gender | Batch-specific | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ethnicity | Batch-specific | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Applications | Drug screening, angiogenesis, tubule formation, immune response, arteriolosclerosis, hypertension, vascular wound healing, inflammation, tissue remodeling, vascular differentiation, oxidative stress, apoptosis, stent development |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Product Format | frozen 1 mL | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Storage Conditions | -130°C or below | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Comments | The HUVEC cells are cryopreserved in the second passage to ensure the highest viability and plating efficiency. ATCC primary pooled HUVECs are derived from 10 individual donors, minimizing the lot-to-lot variability associated with cells derived from single donors. Large lot sizes assure consistency for large-scale studies. A complete solution to propagate pooled HUVECs in low serum conditions with or without the addition of human recombinant VEGF. Use of the Endothelial Cell Growth Kit-VEGF will support a faster rate of proliferation because of the presence of several purified human recombinant (rh) growth factors (rh VEGF, rh EGF, rh FGF basic and rh IGF-1) combined with heparin and hydrocortisone. Use of the Endothelial Cell Growth Kit-BBE, which contains Bovine Brain Extract (BBE), is recommended if a more "authentic," less defined culture medium is desired. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Complete Growth Medium |
Table 1. If using the Endothelial Cell Growth Kit-BBE (ATCC® PCS-100-040), add the indicated volume for each component:
友情鏈接
中國(guó)林業(yè)微生物菌種保藏管理中心
中國(guó)工業(yè)微生物菌種保藏管理中心
中國(guó)普通微生物菌種保藏管理中心
美國(guó)國(guó)家生物技術(shù)信息中心(NCBI)
SIB Bioinformatics Resource Portal
https://www.weibo.com/p/10050
中國(guó)典型培養(yǎng)物保藏中心
ATCC菌株、細(xì)胞
菌株，慢病毒，細(xì)菌，真菌，質(zhì)粒載體
聯(lián)系我們
業(yè)務(wù)咨詢:0574-87157013
郵箱:mingzhoubio@163.com 浙江省寧波市高新區(qū)晶輝路866弄33號(hào)智造港E4幢3樓
Copyright ?2019 寧波明舟生物科技有限公司 mingzhoubio.com All Rights Reserved. 浙ICP備19018319號(hào)-1
|
